Imatinib (Gleevec, Novartis, Basel, Switzerland), formerly referred to as STI571, is an inhibitor of specific protein tyrosine kinases that was targeted to the platelet-derived growth factor (PDGF ...

Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.

July 26, 2006 —The cardiotoxic effects related to the leukemia drug imatinib ( Gleevec in the United States, Glivec elsewhere; Novartis) "is a big surprise," says the researcher heading the team ...

Please provide your email address to receive an email when new articles are posted on . Imatinib interruption resulted in shorter median OS. Interruption also appeared linked to rapid progression ...

September 24, 2010 — Treatment with imatinib (Gleevec) should not be stopped in patients with advanced gastrointestinal stromal tumors (GIST), because interruption of therapy places them at a ...

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study ...

DFS at 3 years increased from 55% with 3 years of imatinib maintenance to 87% with 6 years of maintenance therapy. Patients with an estimated 35-70% risk of relapse derived the most benefit from ...

If you have a certain type of cancer, your doctor may discuss imatinib oral tablets with you. This is a prescription drug that’s used to treat some types of blood cancer and skin cancer.

Imkeldi is supplied as a strawberry-flavored oral solution in a 140mL child resistant tamper-evident bottle. The Food and Drug Administration (FDA) has approved Imkeldi, an oral solution ...

We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to interferon-alfa plus ...

Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 ...

Painful crises in sickle cell disease or sickle cell anemia could potentially be treated using imatinib as a therapeutic option, a small study found. Painful crises that occur in patients with ...